PRZOOM - /newswire/ -
Pasadena, CA, United States, 2009/05/17 - Biomedical news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), which hopes its drug, Ampligen will be approved to treat Chronic Fatigue Syndrome (CFS).
Many have wondered why Hemispherx Biopharma's (AMEX:HEB) share price has doubled during the past two trading sessions, especially without apparent "material events." Now, BioMedReports, the news portal covering the biomedical news and financial sector has issued a special report, complete with video and an interview with the company's CEO, Dr. William A. Carter.
Those who have been following BioMedReport's coverage know that the stock continued to spike today following a 41% surge on Friday as traders anticipate the upcoming FDA decision on approval of the company's key drug candidate- Ampligen® (poly I:poly C12U)- a synthetic being developed for the potential treatment Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS). The stock ended the day on Monday up another 48% and was trading slightly higher after hours.
Chronic Fatigue Syndrome, whose symptoms include widespread muscle and joint pain, cognitive difficulties, chronic, often severe mental and physical exhaustion and other characteristic symptoms in a previously healthy and active person, was largely considered psychosomatic until studies began to prove otherwise. Recently published papers indicate the problem may have it's origins at the genetic level.
"This is a disease that actually involves the genetic machinery, and specifically the machinery involved in mounting an immunological response and also a gene that is involved in energy metabolism," explains Dr. Carter in the report. "We now have a finger print test which can be applied (which didn't exist three or four years ago) and can identify patients at risk. So there has been a sea change in our understanding about the disease."
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars.
Disclosure: No positions.
Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.